|
Indian Pediatr 2020;57:488 |
|
Clippings
|
Tanushree Sahoo
Email:
[email protected]n
|
|
Low dose aspirin for prevention of preterm
delivery in lower middle income countries (ASPIRIN Trial)
(Lancet. 2020;395:285-93)
|
Available evidence from a meta-analysis suggests that aspirin
might decrease the incidence of preterm delivery as well, if initiated
early in gestation. To explore it further, the authors conducted this
multicenter, double blind, placebo controlled trial in seven community
sites from six lower and middle income countries (LMIC) including India.
A total of 11976 nulliparous pregnant women with singleton pregnancy
were randomized to receive either lower dose aspirin (daily dose 81 mg)
or placebo from 6-14 weeks. The incidence of preterm delivery before 37
wk (primary outcome) was lower in intervention arm as compared to
control arm (11.6 % vs 13.1%, RR 0·89, 95% CI 0·81-0·98). In secondary
outcomes, there was a decrease in incidence of perinatal mortality,
early preterm delivery (<34 wk), and incidence of gestational
hypertension in women delivering before 34 wk.
|
|
Fast versus slower increment of milk
feeding in Preterm infants (SIFT trial) (N Engl J Med.
2019;381:1434-43)
|
The researchers involved in this multicenter trial in Ireland randomized
very preterm (<32 wk) or very low birth weight (<1500 g) infants to
faster increment group (daily increment 30 mL/kg) or slower increment
group (daily increment 18 mL/kg) until full feeding was achieved. The
incidence of primary outcome i.e., survival without moderate or severe
neuro-disability at 24 months was similar between the groups (802 of
1224 infants (65.5%) in faster increment and 848 of 1246 (68.1%) in
slower increment group, adjusted RR, 0.96; 95% CI: 0.92-1.01; P=0.16);
so was the incidence of major secondary outcomes like late onset sepsis
(29.8% vs 31.1%) and necrotizing enterocolitis (5.0% vs 5.1%). Thus
faster feeding increment appears a very promising strategy in stable
preterm neonates and should be actively implemented.
|
|
Neonatal hypoglycemia optimal
treatment threshold (HypoEXIT) trial (N Engl J Med.
2020 February 6. doi: 10.1056/NEJMdo005675)
|
Currently, there is no existing consensus regarding optimum treatment
threshold for neonatal hypoglycemia of at risk neonates. The researchers
of this multicenter non-inferiority trial involving 17 teaching
hospitals in Netherlands randomized 689 neonates of >35 weeks with one
or more risk factors for hypoglycemia (small for gestational age, infant
of diabetic mother or large for date) either in to lower threshold group
(treatment initiated at glucose concentration of <35 mg/dL, n=348) or
traditional threshold group (treatment initiated at glucose
concentration of <47 mg/dL, n=341). The primary outcome (assessed in
82.5 % and 86.5% infants in low and traditional threshold groups,
respectively) was defined by Bayley scales of infant and toddler
development, 3rd edition at 18 months of age with a non-inferiority
margin of 7.5 points. There was establishment of non-inferiority for
both cognitive [mean scores (SE), 102.9 (0.7) vs 102.2 (0.7)] and motor
outcome [mean scores (SE), 104.6 (0.7) vs 104.9 (0.7)] between the
groups. The mean glucose concentration was higher in traditional
threshold group [61(0.5) mg/dl vs 57 (0.4) mg/dL]. Though, there were
fewer and less severe hypoglycemic episodes in the traditional-threshold
group, the infants in the group needed more frequent invasive diagnosis
and treatment. However, in view of long term consequences of uncorrected
hypoglycemia and medicolegal aspects, the trial needs to be interpreted
cautiously in the Indian scenario.
|
|
Choice of antenatal corticosteroid for
improving outcomes of preterm birth (ASTEROID) trial
(Lancet Child Adolesc hlth. 2019;3:769-80)
|
Despite established benefits of antenatal corticosteroids (ANS), the
choice of steroid remains a matter of debate. Hence the investigators
tried to compare the maternal and neonatal benefits and side effect of
most commonly used ANS (dexamethasone and betamethasone) in this
randomized, double blind, placebo control, multicenter trial from 14
maternity care units of Australia and New Zealand. Between 2009 to 2013,
1346 eligible consenting pregnant women of gestation <34 wks were
recruited randomly in to dexamethasone arm (n=679, two IM doses of 12 mg
dexamethasone sodium phosphate given 24 h apart) or betamethasone arm
(n=667, two IM doses of 11.4 mg betamethasone given 24 h apart). The
primary outcome death or neurosensory disability at corrected age of 2
years were similar between both the groups (198 (33%) in dexamethasone
group vs 192 (32%) in betamethasone group; adjusted relative risk 0·97,
95% CI 0·83 to 1·13; P=0·66). However, the incidence of maternal side
effects like discomfort at injection site was less in dexamethasone
group (1% vs 3%; P=0·02). Thus, the investigators concluded due to ease
of administration, lower cost and lesser side effect profile
dexamethasone can be a safe alternative ANS.
|
|
|
|